Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
A novel non-invasive method for using carbon-13 magnetization transfer effects to determine and evaluate in vivo aspartate transaminase (AST) activity and levels in an organ, as a biomarker of disease and certain neurological disorders. More
Lotuzol is a new herbal drug composing water extract powder of Nelumbinis Semen to treat depression without sexual dysfunction, a major adverse effect in commonly used anti-depressants. More
The Gait-O-Gram can detect and analyze gait information from an individual and, through the use of fuzzy logic algorithms, determine the presence of neuromuscular symptoms. More
Findings indicate that activation of Nurr1 may be therapeutically useful for Parkinson's disease patients; therefore, the mice would be useful in Parkinson's disease research. More
A simple assay to validate and quantify allele-specific silencing More
Initial results indicate that sodium nitrite can be used as a potential cost-effective platform therapy for a wide variety of disease indications characterized broadly by constricted blood flow or hypoxia. More
CSIC has patented a series of derivatives with neuroprotective activity when subjected to biological evaluation, and its use in a potential treatment of diseases in which oxidative processes play a crucial role, such as the Alzheimer’s disease. More
Reperfusions can lead to severe damage in patients with heart attacks and strokes, the SOD-nanoparticles would be highly beneficial for use in hospitals for treating these patients. More
These analogs may increase water solubility and bioavailability for improved therapeutic formulation and utility More
Methods for administering an Eap agent in an amount that will treat or prevent autoimmune neuroinflammatory diseases such as multiple sclerosis, decrease the infiltration of immune cells to the CNS, and inhibit T cell-endothelial cell interactions. More
Related Reports
Market Research Reports provided by reports.iptechex.com
Sep 2011 - 97 pages - $3,500
Oct 2010 - 53 pages - $1,000
Aug 2008 - 110 pages - $1,040
Dec 2008 - 25 pages - $200
Jan 2010 - $75
Jun 2006 - 1068 pages - $2,495
Jul 2011 - 98 pages - $5,700
Jun 2011 - 99 pages - $5,700
Jan 2010 - $75
Jan 2010 - $75
Your selection
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Therapeutic target
- CNS trauma
- Diabetic neuropathy
- Fibromyalgia
- Muscular dystrophy
- Myasthenia gravis
- Peripheral neuropathy
- Sexual dysfunction
- Smoking cessation
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us